Media Coverage header image

Media Coverage

Advanced Search
  • 10202018
    Carolina Pot Guide

    In a recent article, we discussed secondhand cannabis smoke and why a person has very little chance to generate a positive hair test from it. A few folks wrote to us explaining they had indeed failed a hair test thanks to the secondhand smoke around them and not what they consumed. We got enough responses that we felt the need to delve deeper into the issue around secondhand smoke and hair follicle tests. In 2015, the Cannabist spoke with Quest Diagnostics Employer Solutions Director of Science and Technology, Dr. Barry Sample, about why secondhand smoke should not trigger a positive test. Dr. Sample explained that, “Hair testing detects a pattern of repetitive use and does not detect recent or single (first time) use. Published, peer-reviewed studies to date have not demonstrated the reporting of a hair specimen as positive for marijuana use due to ‘passive’ or ‘incidental’ exposure.” In the case of a failed hair test, subjects can take a second follow-up test. In this case, hair samples are usually washed to remove any secondhand contaminants from the test.

  • 10202018
    One News Page

    Quest Diagnostics used an 18-month leadership development program called LeadingQuest Academy to overhaul its leadership culture and drive new growth. The academy focused on experiential learning through an in-residence program, action learning projects, cross-functional team-building and pre- and post-assessments.

  • 10192018
    Chamber Business News

    In 2015 Arizona passed a law that allowed people to obtain any test offered by a licensed clinical laboratory without a health care provider’s request or authorization. The benefits of the bill largely fell by the wayside when the primary company that supported the bill was found to be lying about their testing process. However, while all eyes were on the downfall of Theranos, Sonora Quest Laboratories started My Lab ReQuest, their own direct-to-consumer blood testing. “Theranos was already in that space. LabCorp had announced, nationally, that they were going to get into the direct-to-consumer space. So, it was an internal business decision on our part to expand direct-to-consumer,” David Dexter, CEO of SQL, said. “I will tell you that I was somewhat of a skeptic that we were truly entering a direct-to-consumer phase in health care, but I gave way completely because once we completely delivered the direct-to-consumer product, within 90 days of rolling it out, the response was much stronger than I had anticipated.”

  • 10172018
    Press Release Point

    Researchers at Dana-Farber Cancer Institute are seeking participants in a new study, funded as part of the Stand Up To Cancer Multiple Myeloma Dream Team, to identify people with conditions that are precursors of multiple myeloma and track their health over time. The study, dubbed PROMISE, will help scientists track the molecular changes that occur as precursor conditions progress to myeloma. This information will be critical in the development of drugs that prevent the disease from advancing and improve patients’ survival. Initial participation in the trial is online or by mail. Local travel for blood draw is required. Testing will be performed at each participant’s local Quest Diagnostics laboratory. To sign up for the study, please visit www.promisestudy.org. Additional funding is provided by grants from the Multiple Myeloma Research Foundation, the Multiple Myeloma Research Consortium, Celgene, Leukemia and Lymphoma Society and the National Institutes of Health. The Promise study has partnered with Quest Diagnostics, as the preferred provider for laboratory testing.

  • 10172018
    NJ Spotlight

    Physicians must be allowed to prescribe opioids, but we need regulations that support drug testing of patients before and during such therapy. Throughout my career, I have closely studied prescription drug use and misuse, particularly relating to opioids. As director, medical science liaison, and medical affairs at the large New Jersey-based company, Quest Diagnostics, the nature of our current opioid epidemic is particularly disturbing, and it’s hitting much too close to home.